Multiple myeloma (MM) is a malignancy of plasma cells (PC) that grow within the bone
marrow and maintain massive immunoglobulin (Ig) production. Disease evolution is driven …

Simple Summary Multiple myeloma treatment has developed enormously within the last two
decades. Most recently immunotherapies have been introduced. Monoclonal antibodies …

Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the
mechanisms underlying this complexity are incompletely understood. We report an analysis …

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …

Simple Summary The growing interest in immunotherapy for the treatment of multiple
myeloma demands a deep knowledge of the complex interactions between malignant and …

Antibody secreting plasma cell plays an indispensable role in humoral immunity. As
activated B cell undergoes germinal center reaction and develops into plasma cell, it …

The knowledge of cancer origin and the subsequent tracking of disease evolution represent
unmet needs that will soon be within clinical reach. This will provide the opportunity to …

Multiple myeloma (MM) is an incurable cancer of antibody secreting plasma cells. Globally, it
accounts for~ 15% of all hematological malignancies and is second only to non-Hodgkin's …

Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In
the absence of a single unifying genetic event contributing to disease manifestation, efforts …

Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal
immunoglobulin (Ig) production. The disease remains incurable due to a multitude of …